Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
about the author
Brittany Meiling
editors@endpointsnews.com
Brittany Meiling on LinkedIn
author articles
IL-2 without the toxic side effects? Orbimed backs the idea in Synthorx' $63M round
8 years ago
Financing
Startups
Crescendo snares $70M Series B for its tumor-fighting tech
8 years ago
Financing
Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant
8 years ago
R&D
Amid hot IPO season, Mereo drops Nasdaq plans citing 'challenging' market conditions
8 years ago
Financing
Venrock-backed startup Corvidia snags $60M round to develop ex-AstraZeneca drug
8 years ago
Financing
After mega-round investment, ADC Therapeutics cans PhI trial in HER2
8 years ago
R&D
'Site-less' trials in mind, Novartis launches an app for ophthalmology research
8 years ago
Pharma
Protein degradation 2.0? Third Rock sinks $56M into Cedilla's unusual approach
8 years ago
Financing
Startups
Bankrupt and weary, diet pill maker Orexigen to sell for $75M to Nalpropion
8 years ago
Deals
R&D
Pfizer hits stumbling block on Herceptin rival, but wins 'breakthrough' status on MenB vaccine
8 years ago
R&D
Pharma
Arcturus takes another legal stab at former CEO as public battle turns serious for the company
8 years ago
People
Pharma
In knockout IPO offerings, MorphoSys and Surface Oncology haul combined $316M in upsized deals
8 years ago
Financing
Pfizer heads to the Hudson, signs 20-year lease at posh new NYC headquarters
8 years ago
Pharma
Magenta bags $52M Series C for bone marrow transplant pipeline
8 years ago
Financing
AstraZeneca licenses Ionis' NASH drug for $30M as momentum builds in the field
8 years ago
Pharma
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
8 years ago
Pharma
Evolus touts equal efficacy for its Botox me-too drug in PhIII European/Canadian trials
8 years ago
R&D
Ferring buys up PhIII microbiome drug with acquisition of Rebiotix
8 years ago
Deals
Harvard big-shots Kevin Eggan and Clifford Woolf launch ALS startup with exclusive Q-State tech
8 years ago
Startups
Biotech gains ground in NYC: Sprawling research center planned in $1.6B Midtown project
8 years ago
Pharma
On the heels of major Pfizer deal, Arvinas snags $55M Series C for protein degradation cancer programs
8 years ago
Financing
Allergan, Richter prep for FDA OK with positive PhIII for cariprazine in bipolar depression
8 years ago
R&D
Backed by giants, antibiotics upstart Macrolide gets $20M and an ex-Novartis exec as CEO
8 years ago
People
Financing
Watch out Alnylam/Ionis: Pfizer’s positive PhIII tafamidis data makes drug a new rival
8 years ago
R&D
First page
Previous page
5
6
7
8
9
10
11
Next page
Last page
